In vitro and in vivo evaluation of PEGylated nanoparticles of bendamustine for treatment of lung cancer

Abstract

The purpose of this study was to develop PEGylated nanoparticles of bendamustine (BM) to improve therapeutic efficiency of drug and reduce the side-effects. The nanoparticles were prepared by a modified diffusion–emulsification method. The particle size and zeta potential of optimized BM-loaded PEGylated NPs were found to be 256 nm and −29.1 mV. The in vitro release showed biphasic behavior, with initial burst release followed by slow sustained delivery. The anti-tumor activity was determined using the A- 549 cell line, by the MTT assay. The stability study revealed that the nanoparticles prepared were stable for 3 months at both 25°C and 4°C.